Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease

: Inflammatory bowel disease (IBD) is a chronic, elusive disorder resulting in relapsing inflammation of intestine with incompletely elucidated etiology, whose two representative forms are ulcerative colitis (UC) and Crohn’s disease (CD). Accumulating researches have revealed that the individual genetic susceptibility, environmental risk elements, intestinal microbial flora, as well as innate and adaptive immune system are implicated in the pathogenesis and development of IBD. Despite remarkable progression of IBD therapy has been achieved by chemical drugs and biological therapies such as aminosalicylates, corticosteroids, antibiotics, anti-tumor necrosis factor (TNF)-α, anti-integrin agents, etc., healing outcome still cannot be obtained, along with inevitable side effects. Consequently, a variety of researches have focused on exploring new therapies, and found that natural products (NPs) isolated from herbs or plants may serve as promising therapeutic agents for IBD through antiinflammatory, anti-oxidant, anti-fibrotic and anti-apoptotic effects, which implicates the modulation on nucleotide- binding domain (NOD) like receptor protein (NLRP) 3 inflammasome, gut microbiota, intestinal microvascular endothelial cells, intestinal epithelia, immune system, etc. In the present review, we will summarize the research development of IBD pathogenesis and current mainstream therapy, as well as the therapeutic potential and intrinsic mechanisms of NPs in IBD.

Download Full-text

P561. Time course and clinical implications of development of binding and neutralizing antibodies against adalimumab in patients with inflammatory bowel disease

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jju027.679 ◽

2015 ◽

Vol 9 (suppl 1) ◽

pp. S360-S361 ◽

Cited By ~ 1

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Neutralizing Antibodies ◽

Time Course ◽

Clinical Implications ◽

Inflammatory Bowel

Download Full-text

Non-conventional dysplastic subtypes in inflammatory bowel disease: a review of their diagnostic characteristics and potential clinical implications

Journal of Pathology and Translational Medicine ◽

10.4132/jptm.2021.02.17 ◽

2021 ◽

Vol 55 (2) ◽

pp. 83-93

Author(s):

Won-Tak Choi

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Clinical Implications ◽

Diagnostic Characteristics ◽

Inflammatory Bowel

Download Full-text

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

Inflammatory Bowel Diseases ◽

10.1002/ibd.22910 ◽

2012 ◽

Vol 18 (12) ◽

pp. 2209-2217 ◽

Cited By ~ 69

Author(s):

Casper Steenholdt ◽

Magid Al-khalaf ◽

Jrn Brynskov ◽

Klaus Bendtzen ◽

Ole. Thomsen ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Clinical Implications ◽

Inflammatory Bowel ◽

Antibody Levels

Download Full-text

Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

Journal of Clinical Medicine ◽

10.3390/jcm9051273 ◽

2020 ◽

Vol 9 (5) ◽

pp. 1273 ◽

Cited By ~ 6

Author(s):

Karma Yeshi ◽

Roland Ruscher ◽

Luke Hunter ◽

Norelle L. Daly ◽

Alex Loukas ◽

...

Keyword(s):

Health Care ◽

Inflammatory Bowel Disease ◽

Natural Products ◽

Bowel Disease ◽

Inflammatory Diseases ◽

Treatment Options ◽

Mucosal Healing ◽

Main Challenge ◽

Long Term Treatment ◽

Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition and immune responses, and various environmental factors. Despite many treatment options, there is no cure for IBD. The increasing incidence and prevalence of IBD and lack of effective long-term treatment options have resulted in a substantial economic burden to the healthcare system worldwide. Biologics targeting inflammatory cytokines initiated a shift from symptomatic control towards objective treatment goals such as mucosal healing. There are seven monoclonal antibody therapies excluding their biosimilars approved by the US Food and Drug Administration for induction and maintenance of clinical remission in IBD. Adverse side effects associated with almost all currently available drugs, especially biologics, is the main challenge in IBD management. Natural products have significant potential as therapeutic agents with an increasing role in health care. Given that natural products display great structural diversity and are relatively easy to modify chemically, they represent ideal scaffolds upon which to generate novel therapeutics. This review focuses on the pathology, currently available treatment options for IBD and associated challenges, and the roles played by natural products in health care. It discusses these natural products within the current biodiscovery research agenda, including the applications of drug discovery techniques and the search for next-generation drugs to treat a plethora of inflammatory diseases, with a major focus on IBD.

Download Full-text